SynthesisCardiovascular and interventional radiology2021
Predictive Factors for Hypertrophy of the Future Liver Remnant After Portal Vein Embolization: A Systematic Review.
Synthesis in Cardiovascular and interventional radiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- CIRSE Standards of Practice on Portal Vein Embolization and Double Vein Embolization/Liver Venous Deprivation.Cardiovascular and interventional radiology · 2024Guideline
- Impact of sarcopenia on the future liver remnant growth after portal vein embolization and associating liver partition and portal vein ligation for staged hepatectomy in patients with liver cancer: A systematic review.Frontiers in oncology · 2022Pooled it
- Imaging biomarkers of liver hypertrophy after portal vein embolization in patients with liver tumors: cholestasis, arterial hyperperfusion, and splenic response.Abdominal radiology (New York) · 2026Article
- Article
- Correlation between intrahepatic iodine quantity after portal vein embolization and future liver remnant hypertrophy.Japanese journal of radiology · 2026Article
- Exploring radiomics as a predictor of hypertrophy of future liver remnant after portal vein embolization in biliary malignancies: a retrospective cohort study.Abdominal radiology (New York) · 2026Article
- CT-defined sarcopenia as a predictive factor in patients undergoing portal vein embolization: a systematic review and meta-analysis.Translational gastroenterology and hepatology · 2026Article
- Enhancing future liver remnant hypertrophy: innovative preoperative strategies and emerging technologies.Translational gastroenterology and hepatology · 2026Review
- A Multiphase CT-Based Radiomics-Clinical Model to Identify Inadequate Future Liver Remnant Hypertrophy After Portal Vein Embolization Before Major Hepatectomy.Cancer management and research · 2026Article
- Liver hypertrophy techniques: a position paper from the Italian Group of Regenerative and Occlusive Worldwide-used techniques of hepatic Hypertrophy (I GROWtoH).Updates in surgery · 2025Article
- Sarcopenia in Interventional Radiology: An Opportunistic Imaging Biomarker for Patient Outcomes and Procedural Planning.Muscles (Basel, Switzerland) · 2025Review
- Augmenting the Future Liver Remnant Prior to Major Hepatectomy: A Review of Options on the Menu.Annals of surgical oncology · 2025Review
- Future liver remnant hypertrophy and postoperative outcomes: a retrospective comparison between segmental and main right portal vein embolization.CVIR endovascular · 2025Article
- ASO Author Reflections: Added Value of Pretreatment CT Radiomics for Accurate Prediction of Liver Hypertrophy Following Portal Vein Embolization.Annals of surgical oncology · 2025Article
- Development and External Validation of a Combined Clinical-Radiomic Model for Predicting Insufficient Hypertrophy of the Future Liver Remnant following Portal Vein Embolization.Annals of surgical oncology · 2025Article
- Effectiveness of Balloon Occlusion in Percutaneous Transhepatic Portal Vein Embolization with Gelatin Sponge: A Single-institutional Retrospective Study.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025Article
- Initial experience with Double-vein Embolization in Hungary.European journal of radiology open · 2024Article
- Current Perspectives and Progress in Preoperative Portal Vein Embolization with Stem Cell Augmentation (PVESA).Stem cell reviews and reports · 2024Review
- Assessment of Segmentary Hypertrophy of Future Remnant Liver after Liver Venous Deprivation: A Single-Center Study.Cancers · 2024Article
- Multi-organ Radiomics-Based Prediction of Future Remnant Liver Hypertrophy Following Portal Vein Embolization.Annals of surgical oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This systematic review was conducted to determine factors that are associated with the degree of hypertrophy of the future liver remnant following portal vein embolization. An extensive search on September 15, 2020, and subsequent literature screening resulted in the inclusion of forty-eight articles with 3368 patients in qualitative analysis, of which 18 studies were included in quantitative synthesis. Meta-analyses based on a limited number of studies showed an increase in hypertrophy response when additional embolization of segment 4 was performed (pooled difference of medians = - 3.47, 95% CI - 5.51 to - 1.43) and the use of N-butyl cyanoacrylate for portal vein embolization induced more hypertrophy than polyvinyl alcohol (pooled standardized mean difference (SMD) = 0.60, 95% CI 0.30 to 0.91). There was no indication of a difference in degree of hypertrophy between patients who received neo-adjuvant chemotherapy and those who did not receive pre-procedural systemic therapy(pooled SMD = - 0.37, 95% CI - 1.35 to 0.61), or between male and female patients (pooled SMD = 0.19, 95% CI - 0.12 to 0.50).The study was registered in the International Prospective Register of Systematic Reviews on April 28, 2020 (CRD42020175708).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.